Barak Capital Becomes Substantial Shareholder in Bank Hapoalim
Translated & summarized from Ice by baba
Barak Capital has become a substantial shareholder in Bank Hapoalim after purchasing approximately 480,000 shares for 36.54 million shekels. The group now holds 2.46% of the bank's equity, valued at around 2.39 billion shekels. The Bakshi family controls Barak Capital, a private trading group. It is unclear if further acquisitions are planned.
The story in 5 lines · by baba
- Barak Capital acquired 480,000 Bank Hapoalim shares for 36.54 million shekels.
- The purchase makes Barak Capital a substantial shareholder with 2.46% of the bank's equity.
- Barak Capital's stake in Bank Hapoalim is now valued at approximately 2.39 billion shekels.
- The Bakshi family controls Barak Capital, a private trading group.
- It remains unknown if Barak Capital plans to increase its stake further.
Barak Capital has acquired a significant stake in Bank Hapoalim, becoming a substantial shareholder. The private trading group purchased approximately 480,000 shares of the bank on the Tel Aviv Stock Exchange for about 36.54 million shekels. Following this acquisition, Barak Capital now holds around 32.91 million shares, representing 2.46% of the bank's equity and 2.52% of its voting rights. The total market value of Bank Hapoalim is approximately 97.05 billion shekels, making Barak Capital's current holdings worth about 2.39 billion shekels. Barak Capital, controlled by the Bakshi family, specializes in trading securities, derivatives, and financial instruments both in Israel and abroad, including proprietary trading. Eyal Bakshi has been associated with the group's trading activities for years. The report does not indicate whether Barak Capital intends to increase its holdings further in Bank Hapoalim.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Other 2
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.